logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Levodopa, carbidopa monohydrate and entacapone intestinal gel for severe motor fluctuations in advanced Parkinson’s Disease

< Back

Levodopa, carbidopa monohydrate and entacapone intestinal gel for severe motor fluctuations in advanced Parkinson’s Disease

Drugs

Neurology and Neurosurgery

September 2021


Levodopa, carbidopa monohydrate and entacapone intestinal gel (LECIG, TRICEL, Lecigon) is in development to treat severe motor fluctuations in advanced Parkinson’s disease (PD). PD is a progressive neurological disease caused by a loss of nerve cells in a particular part of the brain that results in decreased levels of the chemical messenger dopamine. This results in the motor symptoms associated with PD: tremor, slow movement, and muscle stiffness. Initially symptoms are managed with oral levodopa therapy. However, levodopa causes side-effects such as nausea or vomiting, and excessive levodopa doses result in dyskinesias (involuntary twisting hyperkinetic movements) and as PD advances, symptoms may re-emerge between doses (“wearing off”).
LECIG is given through continuous infusion into the intestines and consists of levodopa, carbidopa monohydrate and entacapone. Levodopa can be converted to dopamine in the brain to supplement the low levels in PD patients and improve motor symptoms. Addition of carbidopa and entacapone prevent early breakdown of levodopa before it enters the brain, to make more available for conversion to dopamine. If licenced, LECIG would provide an additional treatment option for patients with advanced PD who are levodopa responsive and who have inadequately controlled motor fluctuations using existing medicinal products.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts